Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > VEGF-B


Brief Information

Name:Vascular endothelial growth factor B
Target Synonym:VEGF-related factor,VRF,VEGFB,VEGF-B,VEGFL,Vascular Endothelial Growth Factor B
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
VE6-H5225 Human Human VEGF-B Protein, His Tag
ACRO Quality

Part of Bioactivity data


Human NRP1, Fc Tag (Cat. No. NR1-H5252) captured on Protein A Chip can bind Human VEGF-B, His Tag (Cat. No. VE6-H5225) with an affinity constant of 23.8 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).


Human VEGF R1 Protein, Fc Tag (Cat. No. VE1-H5253) captured on Protein A Chip can bind Human VEGF-B, His Tag (Cat. No. VE6-H5225) with an affinity constant of 0.52 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Synonym Name



Vascular endothelial growth factor B (VEGFB) is also known as VEGF-related factor (VRF), is a secreted O-glycosylated protein, which belongs to the PDGF/VEGF growth factor family. VEGFB is expressed in all tissues except liver. Highest levels found in heart, skeletal muscle and pancreas. VEGFB is growth factor for endothelial cells. VEGF-B seems to play a role only in the maintenance of newly formed blood vessels during pathological conditions. VEGF-B also plays an important role on several types of neurons. It is important for the protection of neurons in the retina and the cerebral cortex during stroke and of motoneurons during motor neuron diseases such as amyotrophic lateral sclerosis.VEGF-B167 binds heparin and neuropilin-1 whereas the binding to neuropilin-1 of VEGF-B186 is regulated by proteolysis.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Ziv-aflibercept BAY-865321; AVE-0005 Approved Regeneron Pharmaceuticals Inc, Sanofi Zaltrap United States Colorectal Neoplasms Sanofi-Aventis U.S. Llc 2012-08-03 Lymphoma; Breast Neoplasms; Urethral Neoplasms; Brain Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Carcinoma, Mucoepidermoid; Gliosarcoma; Astrocytoma; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Peritoneal Neoplasms; Ureteral Neoplasms; Lung Neoplasms; Prostatic Neoplasms; Uterine Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Neuroendocrine; Glioma; Lymphoma, Non-Hodgkin; Thyroid Neoplasms; Carcinoma, Squamous Cell; Retinal Vein Occlusion; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung; Glioblastoma; Solid tumours; Leiomyosarcoma; Multiple Endocrine Neoplasia Type 1; Leukemia; Carcinoma; Carcinoma, Renal Cell; Carcinoid Tumor; Rectal Neoplasms; Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Leukemia, Myelomonocytic, Chronic; Ovarian Neoplasms; Myelodysplastic Syndromes; Myeloproliferative Disorders; Carcinoma, Transitional Cell; Carcinoma, Papillary; Small Cell Lung Carcinoma; Colonic Neoplasms; Ascites; Lung Diseases; Adenoc Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Reflocibart 2H-10; CSL-346 Phase 2 Clinical Csl Ltd Diabetic Nephropathies Details
PB-101 PB-101 Phase 1 Clinical Panolos Bioscience Inc Solid tumours; Stomach Neoplasms; Neoplasms; Colorectal Neoplasms; Carcinoma, Hepatocellular Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message